News

Read the latest news about issues affecting the neuromuscular disease community.

Blog Post

Newborn Screening for DMD and BMD: MDA Needs Your Help

By MDA Staff | January 15, 2019
clinical-trial-alert-image
Blog Post

Clinical Trial Alert: Orphazyme Seeks Participants for a Phase 3 ALS Study

By MDA Staff | January 11, 2019
clinical-trial-alert-image
Blog Post

Clinical Trial Alert: Catabasis Seeks Participants for a Phase 3 DMD Study

By MDA Staff | January 10, 2019
Blog Post

Wave Life Sciences Announces Phase 2/3 Duchenne Muscular Dystrophy Clinical Trial of Suvodirsen (WVE-210201) Selected for FDA Complex Innovative Trial Designs Pilot Program

By Jeanene Swanson | January 8, 2019
Blog Post

FDA Grants Orphan Drug Designation to Myonexus Therapeutics’ MYO-102 Gene Therapy Drug for Limb-Girdle Muscular Dystrophy Type 2D

By Jeanene Swanson | January 4, 2019
FDA APPROVED text on sticker on blue background with pen
Blog Post

FDA Announces the Approval of TIGLUTIK, an Oral Suspension Form of riluzole, for the Treatment of ALS

By MDA Staff | September 10, 2018
Red seal and imprint "FDA APPROVED" on white surface. FDA - Food and Drug Administration is a federal agency of the United States Department of Health and Human Services. Isolated. 3D Illustration
Blog Post

FDA Approves Radicava to Treat ALS

By Amy Madsen | May 6, 2017
Woman doctor using tablet computer in hospital
Blog Post

National ALS Registry Now Open

By Miriam Davidson | October 19, 2010